Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANGEL R CHINEA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1720029317
CMS profile
32963
Location
GUAYNABO, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$196,275.82

300 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANGEL R CHINEA

NPI 1720029317 · CMS profile ID 32963

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

GUAYNABO, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

300 matching records · $196,275.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 300 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 300.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $29.4310/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849178043 CMS
EMD Serono, Inc. $123.2210/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849183335 CMS
EMD Serono, Inc. $108.6410/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849218079 CMS
E.R. Squibb & Sons, L.L.C. $79.3910/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783641395 CMS
BANNER LIFE SCIENCES, LLC $22.2410/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843741721 CMS
EMD Serono, Inc. $20.3910/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849183927 CMS
Genentech USA, Inc. $17.6010/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888545 CMS
Genentech USA, Inc. $1,800.0010/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888573 CMS
Genentech USA, Inc. $10.6810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888575 CMS
Biogen, Inc. $19.8510/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825355 CMS
EMD Serono, Inc. $120.3010/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849210525 CMS
Novartis Pharmaceuticals Corporation $16.9610/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812636351 CMS
Biogen, Inc. $104.2010/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825335 CMS
Genentech USA, Inc. $20.5210/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888525 CMS
E.R. Squibb & Sons, L.L.C. $1,128.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783641387 CMS
GENZYME CORPORATION $1,796.3410/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485719 CMS
Alexion Pharmaceuticals, Inc. $45.8810/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114783 CMS
AbbVie Inc. $1,750.0010/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794251269 CMS
EMD Serono, Inc. $117.3210/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849153551 CMS
EMD Serono, Inc. $8.1010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849214269 CMS
GENZYME CORPORATION $24.5310/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485687 CMS
Biogen, Inc. $2,825.0010/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825279 CMS
Biogen, Inc. $20.9310/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825333 CMS
E.R. Squibb & Sons, L.L.C. $109.0410/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783641397 CMS
EMD Serono, Inc. $112.7110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849210785 CMS
EMD Serono, Inc. $3,080.0010/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849150221 CMS
Novartis Pharmaceuticals Corporation $8.3910/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812636401 CMS
Biogen, Inc. $24.7209/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825319 CMS
Genentech USA, Inc. $11.8609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888547 CMS
Teva Pharmaceuticals USA, Inc. $139.8609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839507603 CMS
Biogen, Inc. $15.5609/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825317 CMS
Alexion Pharmaceuticals, Inc. $20.0409/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114755 CMS
E.R. Squibb & Sons, L.L.C. $15.9309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783641361 CMS
E.R. Squibb & Sons, L.L.C. $2,932.8009/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783641391 CMS
EMD Serono, Inc. $3,080.0009/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849148049 CMS
EMD Serono, Inc. $3,080.0009/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849149441 CMS
GENZYME CORPORATION $410.2309/17/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485709 CMS
GENZYME CORPORATION $116.1409/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485711 CMS
GENZYME CORPORATION $5,962.3209/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485713 CMS
GENZYME CORPORATION $373.3509/17/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485715 CMS
GENZYME CORPORATION $561.0009/17/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485717 CMS
Biogen, Inc. $1,695.0009/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825263 CMS
EMD Serono, Inc. $96.3809/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849210577 CMS
EMD Serono, Inc. $291.5009/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849150225 CMS
GENZYME CORPORATION $23.4209/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843485685 CMS
Biohaven Pharmaceuticals, Inc. $17.7309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852460101 CMS
Genentech USA, Inc. $1,800.0009/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888569 CMS
Genentech USA, Inc. $9.9609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888571 CMS
EMD Serono, Inc. $84.6009/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849210551 CMS
Biogen, Inc. $1,695.0009/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825261 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $317,786.33 403
PY2020 $185,726.05 245
PY2021 $196,275.82 300
PY2022 $279,334.72 321
PY2023 $246,085.30 281
PY2024 $248,405.51 268
PY2025 $266,405.69 279

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,684.96 3
PY2025 Principal investigator $1,907,962.24 33
PY2024 Principal investigator $2,078,888.10 19
PY2023 Recipient $1,351.01 1
PY2023 Principal investigator $2,399,942.64 26
PY2022 Recipient $6,147.00 5
PY2022 Principal investigator $2,541,163.26 22
PY2021 Recipient $673.00 2
PY2021 Principal investigator $1,098,425.63 28
PY2020 Principal investigator $432,608.52 30
PY2019 Recipient $2,838.49 7
PY2019 Principal investigator $1,131,727.12 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $17,700.00 11/30/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200235
Recipient Novartis Pharmaceuticals Corporation $509.29 11/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291303
Principal investigator 1 TG Therapeutics, Inc. $24,250.00 11/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200233
Principal investigator 1 TG Therapeutics, Inc. $5,450.00 09/30/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200207
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117939
Principal investigator 1 EMD Serono, Inc. $978.00 09/22/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118221
Principal investigator 1 TG Therapeutics, Inc. $20,600.00 08/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200205
Principal investigator 1 Genentech, Inc. $11,673.00 08/22/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583833
Principal investigator 1 TG Therapeutics, Inc. $7,525.00 07/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200203
Principal investigator 1 TG Therapeutics, Inc. $4,198.50 07/31/2025 Non-covered Recipient Entity
The University of Texas at Austin
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200525
Recipient Novartis Pharmaceuticals Corporation $3,370.12 07/30/2025 Covered Recipient Physician COMB157GUS07 No dispute reported 06/30/2026 1190292535
Principal investigator 1 Celgene Corporation $5,344.00 06/25/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research Inc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306473
Principal investigator 1 Novartis Pharmaceuticals Corporation $574,505.94 06/24/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190306921
Principal investigator 1 EMD Serono, Inc. $20,293.00 06/23/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118214
Principal investigator 1 Genentech, Inc. $20,157.30 06/19/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583822
Recipient Novartis Pharmaceuticals Corporation $2,805.55 06/03/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190291676
Principal investigator 1 TG Therapeutics, Inc. $36,750.00 06/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200167
Principal investigator 1 EMD Serono, Inc. $22,598.00 05/26/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118217
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117943
Principal investigator 1 Genentech, Inc. $5,947.20 04/17/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583827
Principal investigator 1 TG Therapeutics, Inc. $41,525.00 03/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200165
Principal investigator 1 EMD Serono, Inc. $300.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117947
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117951
Principal investigator 1 Hoffmann-La Roche Limited $4,659.30 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583806
Principal investigator 1 Hoffmann-La Roche Limited $658.75 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583811
Principal investigator 1 Hoffmann-La Roche Limited $3,507.10 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583815
Principal investigator 1 Genentech, Inc. $2,073.60 03/05/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583818
Principal investigator 1 TG Therapeutics, Inc. $52,850.00 02/28/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200163
Principal investigator 1 Novartis Pharmaceuticals Corporation $315.88 02/10/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A phase IV, prsopective, multicenter, open-label, mother-milk study to evaluate ofatumumab concentration in the breast milk of lactating women with Relapsing forms of Multiple Sclerosis (RMS) receving kesimpta (ofatumumab) No dispute reported 06/30/2026 1190306917
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 02/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200161
Principal investigator 1 Genentech, Inc. $7,793.00 01/29/2025 Non-covered Recipient Entity
CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211584000
Principal investigator 1 Genentech, Inc. $3,000.00 01/29/2025 Non-covered Recipient Entity
CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211584005
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,320.09 01/07/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306915
Principal investigator 1 Novartis Pharmaceuticals Corporation $961,629.58 01/06/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190306919
Principal investigator 1 TG Therapeutics, Inc. $13,250.00 01/06/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200159
Principal investigator 1 Novartis Pharmaceuticals Corporation $840.00 01/01/2025 Non-covered Recipient Entity
THE SAN JORGE HOSPITAL, INC
A two year double blind randomized multicenter active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon beta 1a i m once weekly in pediatric patients with relapsing remitting multiple scler No dispute reported 06/30/2026 1190302077